Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

About this update from Kala Bio, Inc.

[{"type":"image","alt":"KALA BIO, Inc.","displaySize":"","headline":null,"caption":"KALA BIO, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":210,"url":"https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/poFKt69Bd.mweg6BAiQGYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46","width":300,"height":210}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry","length":191,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":191,"olType":false},{"type":"text","content":"TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”). The engagement will deploy Kala Bio’s purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.","length":740,"tagName":"p"},{"type":"text","content":"Red Light recently announced a definitive arrangement agreement to acquire Filament’s business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010.","length":318,"tagName":"p"},{"type":"text","content":"Strategic Rationale","length":19,"tagName":"p"},{"type":"text","content":"The engagement of the Kala’s Researgency.ai platform represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it expands its regulated psychedelic drug development platform. By deploying custom purpose-built AI ...

More updates from Kala Bio, Inc.